Evidence map›Paper›PMID 40667371›Full record

ArticlebioRxiv : the preprint server for biology2025

Neurobiological and Chemical Characterization of the Cyanobacterial Metabolite Veraguamide E.

Jesus Sotelo, Sahar Mofidi Tabatabaei, Christian Fofie, Kelvin Fosu, Joseph Dodd-O, Rebecca Simcik, See Tack, Miguel J Soto-Reyes, Saad Yousef, Eduardo J Caro-Diaz and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Jesus SoteloDepartment of Biological Sciences, Department of Neuroscience, and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, TX.
Sahar Mofidi TabatabaeiDepartment of Pharmaceutical Sciences, University of Kentucky, Lexington, KY.ORCID 0000-0002-6193-8137
Christian FofieDepartment of Biological Sciences, Department of Neuroscience, and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, TX.ORCID 0000-0001-6148-7578
Kelvin FosuBiodesign Center for Personalized Diagnostics and School of Molecular Sciences, Arizona State University, Tempe, AZ.
Joseph Dodd-ODepartment of Biomedical Engineering, New Jersey Institute of Technology, Newark, NJ.
Rebecca SimcikDepartment of Biological Sciences, Department of Neuroscience, and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, TX.
See TackDepartment of Biological Sciences, Department of Neuroscience, and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, TX.
Miguel J Soto-ReyesDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico - Medical Sciences Campus, San Juan, PR.
Saad YousefDepartment of Biological Sciences, Department of Neuroscience, and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, TX.ORCID 0000-0003-0829-8182
Eduardo J Caro-DiazDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico - Medical Sciences Campus, San Juan, PR.
Vivek KumarDepartment of Biomedical Engineering, New Jersey Institute of Technology, Newark, NJ.
Wade Van HornBiodesign Center for Personalized Diagnostics and School of Molecular Sciences, Arizona State University, Tempe, AZ.ORCID 0000-0002-2493-5578
Benedict J KolberDepartment of Biological Sciences, Department of Neuroscience, and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, TX.
Kevin J TidgewellDepartment of Pharmaceutical Sciences, University of Kentucky, Lexington, KY.ORCID 0000-0002-0501-2604

Funding

Understanding the role of anti-apolipoprotein A-I antibodies in atherosclerotic cardiovascular diseaseP20GM130456 · NIGMS · UNIVERSITY OF KENTUCKY · PI Jon Scott Thorson · 2020 to 2026
$18.7M
Planning Study for the Development of Sigma 2 ligands as AnalgesicsR61NS127271 · NINDS · UNIVERSITY OF KENTUCKY · PI KOLBER, BENEDICT J, TIDGEWELL, KEVIN JOSEPH · 2023 to 2023
$1.5M
NIGMS NIH HHS P20 GM130456NINDS NIH HHS R61 NS127271
6 · The paper itself

Abstract

Ver E's structure was validated by

Indexed as

computational dockingCyanobacterianatural productsNMR-ligand bindingSigma-2/TMEM97veraguamides

Identifiers

PMID40667371
PMCPMC12262354

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.